# SANCC: Clinical Trial Early Intervention

> **NCT03950037** · PHASE2 · WITHDRAWN · sponsor: **Oregon Health and Science University**

## Conditions studied

- Subarachnoid Neurocysticercosis

## Interventions

- **DRUG:** Albendazole

## Key facts

- **NCT ID:** NCT03950037
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-04
- **Final completion:** 2023-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to complete due to SARS-CoV-2 pandemic
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950037, "SANCC: Clinical Trial Early Intervention". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03950037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*